# **AMARA RAJA ENERGY & MOBILITY LTD**

Rating: ◀▶ | Target price: ◀▶ | EPS: ▲

### **ONE YEAR OUTLOOK**

### Business & Earnings

- Maintain our ADD rating on ARENM with a TP of Rs. 1,035. ARE&M is likely to benefit from healthy aftermarket growth and thrust on export segment (albeit weak in FY26). We believe the advent of alternate fuel vehicles (CNG, LNG etc.) would aid lead acid growth. We factor in steady pickup in demand for lithium battery pack and EV chargers (1HFY26 revenues of Rs. 2.9bn) as AREN&M leverages its existing relationships across automotive and industrial clientele. ARENM's 16 GWH Li-ion cell manufacturing facility in Telangana would be commissioned in a staggered manner with 2 GWH (phase-1) NMC capacity expected by 4QFY27. However, we believe partial benefits of li-ion manufacturing are factored in, especially ARE&M's strategic agreement with Ather Energy & favourable sourcing benefits from tie-up with GIB (Gotion) for LFP & Jiangsu Highstar for NMC.
- In 2QFY26, lead acid revenues were up 5% YoY aided by healthy growth in automotive OEM (~30% YoY) and aftermarket (2W/4W 2%/flat YoY). Industrial segment declined ~11% YoY as telecom segment declined 35% YoY due to ongoing transition to Li-ion. Revenue from EV chargers & Lithium Battery Packs was at Rs. 1.7bn, up 70% YoY, due to incremental supplies to telecom sector. We pencil in an overall revenue growth of ~7% (FY25-28E). EBITDA margins was up 50bps QoQ as benefits of RM cost (330bps QoQ) was offset by higher other expenses (220 bps). Margins are likely to improve led by commissioning of lead smelting unit and shift from traded to manufacturing of tubular batteries in FY27E.
- Expect FY26-FY28E capex at ~Rs. 38bn towards 1) Li-ion cell capacities, 2) existing line expansion and 3) maintenance capex.

### **Valuation Multiples**

Our TP of Rs. 1,035 is based on 16x Sep-27E (roll forward from FY27) EPS with Rs. 974 from lead acid and Rs. 63 from Li-ion operations (DCF-based due to back-ended benefits). The multiple factors in robust growth in lead acid aftermarket & export segment, coupled with margin expansion led by operating efficiencies.

### FINANCIAL SUMMARY

FINANCI	AL SUIVIIVIARY						
	Net Sales (Rs mn)	EBITDA (%)	PAT (Rs mn)	EPS (Rs)	P/E (x)	EV/EBITDA (x)	ROE (%)
FY24	1,12,603	14.4	9,059	49.5	20	11	14
FY25	1,24,049	13.1	9,639	52.7	19	11	14
FY26E	1,35,119	12.4	9,672	52.9	21	11	11
FY27E	1,45,600	14.0	11,352	62.0	16	8	13
FY28E	1,55,784	14.0	12,406	67.8	14	8	13

CMP Rs. 980 Target Price Rs. 1,035

Rating ADD



### THREE YEAR OUTLOOK

### Business & Earnings

- In June 2024, ARACT (100% subsidiary of ARENM) announced a technical licensing agreement with GIB EnergyX Slovakia s.r.o.(GIB), a JV between Gotion High-Tech Co Ltd, China and InoBat, Slovakia. The agreement allows ARACT to 1) access cell technology IP, 2) seek support to establish Gigafactory facilities confirming the latest generation process technologies, 3) integrate with Gotion's global supply chain network for critical battery materials, and 4) provide customer technical support for solution deployment. The company had developed the 2170 NMC cell in its Advanced Lithium Technology Research Hub in collaboration with Jiangsu Highstar. The company intends to set up 16 GWH cell manufacturing capacities (Phase 1: 2GWH by FY27 focused on NMC chemistry, Phase 2: 8 GWH by FY30). ARENM aims to send test samples to secure approvals from various OEMs & fleet operators for commercial supplies, and we expect benefits to accumulate in the long run.
- ARENM's growth in lead acid would be led by an increasing market share in export, AM/OEM markets. The company plans to enhance its footprint in the export market wherein it has incorporated many subsidiaries. ARENM also plans to establish a strong presence in the motive power space due to the thrust on warehousing. However, the growing competitive intensity would be a key monitorable for margin expansion.

### Valuation Multiples <->

■ Expect ARENM to report a consolidated revenue and EBITDA CAGR of 9% & 10%, respectively, over FY25-29E. While return ratios are likely to be under duress due to significant capex, anticipate ramp-up in li-ion capacities to improve operating efficiencies/return profile.

### **KEY ESTIMATES REVISION**

		FY26E		FY27E			
	Old	New	Change	Old	New	Change	
Sales	1,33,935	1,35,119	1%	1,44,186	1,45,600	1%	
EBITDA (%)	12.7	12.4	-30 bps	14.0	14.0	0 bps	
PAT	8,897	8,665	-3%	11,194	11,352	1%	
EPS	48.6	47.3	-3%	61.2	62.0	1%	
PE	Before	Results:	16.0	After F	Results:	16.0	

All figures in Rs.Mn

\*EBITDA margins declined due to an exceptional of ~Rs. 1.2 bn (Business Interruption

# OUTLOOK REVIEW 2QFY26 10 November 2025

Industry	AUTOMOBILE
<b>Key Stock Data</b>	
Bloomberg	ARENM IN
Shares o/s	183mn
Market Cap	Rs. 179bn (\$2,023mn)
52-wk High-Low	Rs. 1,360-805
3m ADV	Rs. 511mn (\$6mn)
F&O	Yes

### Latest Shareholding (%)

	Mar-25	Jun-25	Sep-25
Promoters	32.9	32.9	32.9
Institutions	35.2	35.3	34.2
Public	31.9	33.8	32.9
Pledge	0.0	0.0	0.0

#### **Stock Performance (%)**

	1m	3m	12m
ARENM	-2.0	4.6	-24.1
Sensex	1.3	4.2	4.7

### **RESEARCH ANALYSTS**

# Mukesh Saraf

mukesh.s@avendusspark.com +91 44 4344 0041

### Ramakrishnan Seshan

Ramakrishnan.s@avendusspark.com +91 44 4344 0020

### N.J. Krupashankar

krupashankar.n@avendusspark.com +91 44 4344 0098

insurance claim - Chittoor plant fire.
find AVENDUS SPARK RESEARCH on Bloomberg [RESP SPAK <go>] | FACTSET | REFINITIVE Webster | Page 1



## **Quarterly Financial Statement**

- Standalone revenue for the quarter came in at ~Rs. 33.9 bn, up ~8% YoY and up 1% QoQ.
- Based on segmental disclosures (consolidated), lead acid segment revenue was at Rs. 33.0 bn, up 5% YoY and up 1% QoQ. Lead acid EBIT margins was at 11.9%, up 420 bps QoQ. Li-ion revenues was at Rs. 1.7 bn, up 69% YoY and up 40% QoQ. Li-ion EBIT margins was at -28.7%.
- Gross margin at 32.8%, increased ~330 bps QoQ.
- Absolute employee costs increased 17% YoY. As % of revenue, the same was up 70 bps QoQ.
   Absolute other expenses increased 25% YoY. As % of revenue, the same was up 220 bps QoQ.
- Consequently, EBITDA came in at Rs. 4.1 bn, down 8% YoY and up 5% QoQ. EBITDA margin came in at 12.0%, up 40 bps QoQ.
- Depreciation for the quarter at Rs. 1.38 bn was up ~13% YoY. Other income came in at Rs. 241 mn, up 30% YoY.
- During the quarter, the company recognized an exceptional item of ~Rs. 1.2 bn as a Business Interruption insurance claim related to the 30-Jan-2023 Chittoor plant fire.
- PAT adjusted for exceptional items for the quarter stood at Rs. 2.1 bn, down 13% YoY and up 9% QoQ.
- The company infused ~Rs. 3.5bn in the quarter into its wholly-owned subsidiary, Amara Raja Advanced Cell Technologies Pvt Ltd (ARACT) towards equity; cumulative investment in ARACT now stands at ~Rs. 12bn.

#### **Standalone Financial Results**

Rs. mn\Period	2QFY26	2QFY25	yoy Growth	1QFY26	qoq Growth	1HFY26	1HFY25	Yoy Growth
Revenue	33,882	31,358	8.0%	33,499	1.1%	67,381	62,670	7.5%
Raw Material	22,776	21,212	7.4%	23,629	-3.6%	46,404	42,775	8.5%
Employee Cost	2,231	1,899	17.5%	1,976	12.9%	4,207	3,755	12.0%
Other Expenses	4,816	3,841	25.4%	4,028	19.6%	8,844	7,430	19.0%
Total Expenditure	29,822	26,952	10.7%	29,633	0.6%	59,455	53,960	10.2%
EBITDA	4,059	4,407	-7.9%	3,867	5.0%	7,926	8,710	-9.0%
Margin %	12.0%	14.1%	-207 bps	11.5%	44 bps	11.8%	13.9%	-214 bps
D&A	1,380	1,220	13.1%	1,292	6.8%	2,672	2,403	11.2%
EBIT	2,679	3,186	-15.9%	2,574	4.1%	5,254	6,307	-16.7%
Other income	241	185	30.4%	139	72.7%	380	440	-13.6%
Net Interest exp (inc)	82.6	131.3	-37.1%	103.5	-20.2%	186.1	221.0	-15.8%
РВТ	2,838	3,240	-12.4%	2,610	8.7%	5,448	6,526	-16.5%
Tax provision	1,032	833	23.9%	670	54.0%	1,702	1,674	1.7%
Tax rate %	36.4%	25.7%	1065 bps	25.7%	1068 bps	31%	26%	559 bps
PAT (Reported)	3,024	2,407	25.6%	1,940	55.9%	4,964	4,853	2.3%
PAT (Adjusted)	2,097	2,407	-12.9%	1,929	8.7%	4,026	4,853	-17.0%
Adjusted PAT Margin %	6.2%	7.7%	-149 bps	5.8%	43 bps	6.0%	7.7%	-177 bps
Shares Outstanding	183	183		183		183	183	
EPS (Reported)	16.5	13.2	25.6%	10.6	55.9%	27.1	26.5	2.3%
EPS (Adjusted)	11.5	13.2	-12.9%	10.5	8.7%	22.0	26.5	-17.0%

Source: Company data, Avendus Spark Research



## **Abridged Financials**

	Abridged i manerais								
New North No.   10.14   11.19   12.35   13.17   14.20   15.20   163.0   174.5   174.	in Rs. Bn	FY23	FY24	FY25	FY26E	FY27E	FY28E	FY29E	FY30E
Part	Standalone operations (Lead Acid)								
SelTOA   14.3   16.1   16.2   16.3   19.9   21.3   22.8   24.4     A	Revenues	101.4		123.5			152.0		
Part	YoY (%)		10%	10%	7%	8%	7%	7%	
PAT	EBITDA								
PAT   PAT	EBITDA (%)	14.1%	14.4%	13.1%	12.4%	14.0%	14.0%	14.0%	14.0%
Next Block   36.9   35.5   34.7   35.3   34.4   33.1   32.0   30.6   Advance Cell Fest subsidiary (Non- decided in Section 19.5   12.1   19.4   28.4   30.9   41.9   52.5   62.7	PAT	7.8	9.0	8.8	8.5	10.7	11.5	12.4	13.3
Advance Cell Tech subsidiary (Non-curre in invastment) 4.6 12. 13.7 2.3 0.4 7.0 6.3 6.4 7.9 14.0 17.1 14.5 11.1 10.8 11.4 12.2 13.1 14.0 14.0 15.2 13.1 14.0 15.2 13.1 14.0 15.2 13.1 14.0 15.2 15.3 16.3 16.4 7.9 16.3 16.4 7.9 16.3 16.4 7.9 16.3 16.4 7.9 16.0 16.3 16.4 7.9 16.0 16.3 16.4 7.9 16.0 16.3 16.4 7.9 16.0 16.3 16.4 7.9 16.0 16.3 16.4 7.9 16.0 16.0 16.0 16.0 16.0 16.0 16.0 16.0	PAT (%)	7.7%	8.0%	7.2%	6.4%	7.6%	7.5%	7.6%	7.6%
Current investment) 4.6 1.1. 1.9.4 2.8.4 3.0.9 4.19 3.0.4 3.0.4 3.0.9 4.19 3.6.5 3.6.4 3.9 8.10 8.10 1.1. 1.1. 1.1. 1.1. 1.1. 1.1.	Net Block	36.9	35.5	34.7	35.3	34.4	33.1	32.0	30.6
Net Working Capital	Advance Cell Tech subsidiary (Non- current investment)	4.6	12.1	19.4	28.4	30.9	41.9	52.5	62.7
NWCdays   62   47   33   30   29   29   29   29   29   29   29   2	Cash & cash equivalents	1.2	3.7	2.3	0.4	7.0	6.3	6.4	7.9
Capital Employed - Lead Acid   59.9   65.9   65.9   67.5   74.8   83.7   93.5   104.0   115.2	Net Working Capital	17.1	14.5	11.1	10.8	11.4	12.2	13.1	14.0
Capital Employed - Lead Acid   59.9   65.9   65.9   67.5   74.8   83.7   93.5   104.0   115.2	NWC days	62	47		30	29		29	29
Revenues	Capital Employed - Lead Acid	59.9	65.9	67.5	74.8	83.7	93.5	104.0	115.2
Revenues									
Marie   Mari	Li-Ion cell manufacturing operations								
FBITDA   F	Revenues				0.0	0.0	8.8		
PBT   PBT	YoY (%)								
PBT   PBT	EBITDA				0.0	0.0		0.0	0.8
PBT	EBITDA (%)						-5.0%	0.0%	2.5%
Net Block	PBT		Immaterial		0.4	0.4	-1.8	-2.2	-2.2
Net Working Capital Now Capital Now Capital Employed - Li-ion   Now Capital Employed - Li-io	PBT (%)						-20.7%	-10.9%	-7.1%
September   1908   19	Net Block				15.8	18.3	27.7	35.8	42.9
Consolidated   Cons	Net Working Capital				0.0	0.0	0.7	1.7	2.5
Consolidated   Cons	NWC days				30	30	30	30	30
Revenues         103.9         117.1         128.5         131.7         142.0         160.8         183.3         205.3           EBITDA         YOY (%)         13%         10%         3%         8%         13%         14%         12%           EBITDA (*)         14.4         16.5         16.1         15.8         20.0         21.6         23.8         26.3           EBIT (*)         13.8%         14.1%         12.5%         12.0%         14.1%         13.5%         13.0%         12.8%           EBIT (*)         9.6         11.6         11.0         10.1         13.9         13.4         14.4         15.9           PAT         9.2%         9.9%         8.6%         7.7%         9.8%         8.3%         7.9%         7.7%           PAT         7.6         9.2         8.6         8.2         10.9         10.5         11.2         12.3           Net Block         36.9         39.4         42.0         51.3         52.8         60.5%         6.1%         6.0%           Net Block         36.9         39.4         42.0         51.3         52.8         60.5         67.3         72.6           Cash & cash equivalents	Capital Employed - Li-ion				15.8	18.3	28.4	37.5	45.4
Revenues         103.9         117.1         128.5         131.7         142.0         160.8         183.3         205.3           EBITDA         YOY (%)         13%         10%         3%         8%         13%         14%         12%           EBITDA (*)         14.4         16.5         16.1         15.8         20.0         21.6         23.8         26.3           EBIT (*)         13.8%         14.1%         12.5%         12.0%         14.1%         13.5%         13.0%         12.8%           EBIT (*)         9.6         11.6         11.0         10.1         13.9         13.4         14.4         15.9           PAT         9.2%         9.9%         8.6%         7.7%         9.8%         8.3%         7.9%         7.7%           PAT         7.6         9.2         8.6         8.2         10.9         10.5         11.2         12.3           Net Block         36.9         39.4         42.0         51.3         52.8         60.5%         6.1%         6.0%           Net Block         36.9         39.4         42.0         51.3         52.8         60.5         67.3         72.6           Cash & cash equivalents									
March   Marc	<u>Consolidated</u>								
EBITDA         14.4         16.5         16.1         15.8         20.0         21.6         23.8         26.3           EBIT (PACK)         13.8%         14.1%         12.5%         12.0%         14.1%         13.5%         13.0%         12.8%           EBIT (PACK)         9.6         11.6         11.0         10.1         13.9         13.4         14.4         15.9           PAT (PACK)         9.2%         9.9%         8.6%         7.7%         9.8%         8.3%         7.9%         7.7%           PAT (PACK)         7.6         9.2         8.6         8.2         10.9         10.5         11.2         12.3           PAT (PACK)         7.3%         7.8%         6.7%         6.2%         7.7%         6.5%         6.1%         6.0%           Net Block         36.9         39.4         42.0         51.3         52.8         60.5         67.3         72.6           Cash & cash equivalents         1.2         3.7         2.3         0.4         7.0         6.3         6.4         7.9           Net Working Capital         17.1         14.5         11.1         10.8         11.4         12.9         14.7         16.5           NW	Revenues	103.9							
EBITDA (%)         13.8%         14.1%         12.5%         12.0%         14.1%         13.5%         13.0%         12.8%           EBIT (%)         9.6         11.6         11.0         10.1         13.9         13.4         14.4         15.9           EBIT (%)         9.2%         9.9%         8.6%         7.7%         9.8%         8.3%         7.9%         7.7%           PAT (*)         7.6         9.2         8.6         8.2         10.9         10.5         11.2         12.3           PAT (*)         7.3%         7.8%         6.7%         6.2%         7.7%         6.5%         6.1%         6.0%           Net Block         36.9         39.4         42.0         51.3         52.8         60.5         67.3         72.6           Cash & cash equivalents         1.2         3.7         2.3         0.4         7.0         6.3         6.4         7.9           Net Working Capital         17.1         14.5         11.1         10.8         11.4         12.9         14.7         16.5           Net Working Capital         6.0         45         32         30         29         29         29         29	YoY (%)								
EBIT         9.6         11.6         11.0         10.1         13.9         13.4         14.4         15.9           PAT         EBIT (%)         9.2%         9.9%         8.6%         7.7%         9.8%         8.3%         7.9%         7.7%           PAT         7.6         9.2         8.6         8.2         10.9         10.5         11.2         12.3           PAT (%)         7.3%         7.8%         6.7%         6.2%         7.7%         6.5%         6.1%         6.0%           Net Block         36.9         39.4         42.0         51.3         52.8         60.5         67.3         72.6           Cash & cash equivalents         1.2         3.7         2.3         0.4         7.0         6.3         6.4         7.9           Net Working Capital         17.1         14.5         11.1         10.8         11.4         12.9         14.7         16.5           NWC days         60         45         32         30         29         29         29         29         29	EBITDA					20.0		23.8	
EBIT (%)         9.2%         9.9%         8.6%         7.7%         9.8%         8.3%         7.9%         7.7%           PAT         7.6         9.2         8.6         8.2         10.9         10.5         11.2         12.3           PAT (%)         7.3%         7.8%         6.7%         6.2%         7.7%         6.5%         6.1%         6.0%           Net Block         36.9         39.4         42.0         51.3         52.8         60.5         67.3         72.6           Cash & cash equivalents         1.2         3.7         2.3         0.4         7.0         6.3         6.4         7.9           Net Working Capital         17.1         14.5         11.1         10.8         11.4         12.9         14.7         16.5           NWC days         60         45         32         30         29         29         29         29         29	EBITDA (%)		14.1%		12.0%	14.1%	13.5%	13.0%	12.8%
PAT         7.6         9.2         8.6         8.2         10.9         10.5         11.2         12.3           PAT (%)         7.3%         7.8%         6.7%         6.2%         7.7%         6.5%         6.1%         6.0%           Net Block         36.9         39.4         42.0         51.3         52.8         60.5         67.3         72.6           Cash & cash equivalents         1.2         3.7         2.3         0.4         7.0         6.3         6.4         7.9           Net Working Capital         17.1         14.5         11.1         10.8         11.4         12.9         14.7         16.5           NWC days         60         45         32         30         29         29         29         29         29	EBIT								
PAT (%)         7.3%         7.8%         6.7%         6.2%         7.7%         6.5%         6.1%         6.0%           Net Block         36.9         39.4         42.0         51.3         52.8         60.5         67.3         72.6           Cash & cash equivalents         1.2         3.7         2.3         0.4         7.0         6.3         6.4         7.9           Net Working Capital         17.1         14.5         11.1         10.8         11.4         12.9         14.7         16.5           NWC days         60         45         32         30         29         29         29         29	EBIT (%)								
Net Block     36.9     39.4     42.0     51.3     52.8     60.5     67.3     72.6       Cash & cash equivalents     1.2     3.7     2.3     0.4     7.0     6.3     6.4     7.9       Net Working Capital     17.1     14.5     11.1     10.8     11.4     12.9     14.7     16.5       NWC days     60     45     32     30     29     29     29     29     29	PAT	7.6	9.2	8.6	8.2	10.9	10.5	11.2	12.3
Cash & cash equivalents     1.2     3.7     2.3     0.4     7.0     6.3     6.4     7.9       Net Working Capital     17.1     14.5     11.1     10.8     11.4     12.9     14.7     16.5       NWC days     60     45     32     30     29     29     29     29	PAT (%)	7.3%	7.8%	6.7%	6.2%	7.7%	6.5%	6.1%	6.0%
Net Working Capital         17.1         14.5         11.1         10.8         11.4         12.9         14.7         16.5           NWC days         60         45         32         30         29         29         29         29         29	Net Block	36.9		42.0	51.3	52.8	60.5		72.6
Net Working Capital         17.1         14.5         11.1         10.8         11.4         12.9         14.7         16.5           NWC days         60         45         32         30         29         29         29         29         29	Cash & cash equivalents	1.2	3.7	2.3	0.4	7.0	6.3	6.4	7.9
NWC days 60 45 32 30 29 29 29 29	Net Working Capital		14.5						
		60					29	29	
	Capital Employed - Consolidated								

Avendus<sup>^</sup>

Our base case analysis indicates that li-ion business is valued at Rs. 9bn assuming a projected utilization level of 16 GWh (85% utilization level) and margins of 9% for FY35. Also, the LAB segment contributes Rs. 974/share to an overall TP of Rs. 1,035

Amara: Li-ion Batteries (Li-Ion)	FY23-25	FY26	FY27	FY28	FY29	FY30	FY31	FY32	FY33	FY34	FY35
Revenue (Rs. Bn)		0.0	0.0	8.8	20.3	30.8	39.5	52.8	69.0	88.4	97.3
YoY (%)					131%	51%	28%	34%	31%	28%	10%
EBITDA (Rs. Bn)		0.0	0.0	-0.4	0.0	0.8	2.0	3.7	5.2	7.1	8.8
% Margins	Immaterial			-5.0%	0.0%	2.5%	5.0%	7.0%	7.5%	8.0%	9.0%
Capex (Rs. Bn)		9.0	2.6	11.0	10.6	10.2	12.6	12.3	11.6	11.3	7.0
FCFF (Rs. Bn)		-9.0	-2.6	-12.2	-11.5	-10.3	-11.4	-9.7	-7.8	-5.9	1.0
RoIC (%)		0%	0%	-7%	-6%	-4%	-3%	-1%	0%	1%	3%

Lithium-Ion Operations	FY27			
Terminal Growth (%)	6%			
WACC (%)	13%			
Discounted FCFF (Rs. Bn)	-34.0			
PV of Terminal Value (Rs. Bn)	39.1			
EV (Rs. Bn)	5.1			
Less: Net Debt/(net Cash) (Rs. Bn)	-4.7			
Implied Market Cap (Rs. Bn)	9.8			
Outstanding Shares (Mn)	171			
Target Price (Rs.)	57			

<b>Key Assumptions</b>				
		FY26	FY30	FY35
	Capacities (GWh)	2.0	6.5	15.5
	Utilisation (%)	0%	60%	75%
	Battery Pack (\$/KWh)	102	91	96

- Factoring higher li-ion adoption across automotive, telecom, and energy storage solutions for key end-user industries.
- Margins estimated to be lower than EXIDE due to lack of sourcing tie-up and technical partnership.
- Incremental capex per GWh estimated to reduce with increasing scale

Amara: Consolidated (LaB + Li-ion)	FY23	FY24	FY25	FY26	FY27	FY28	FY29	FY30	FY31	FY32	FY33	FY34	FY35
RoIC (%)	13%	16%	15%	13%	16%	15%	14%	14%	14%	15%	16%	17%	19%


	FY27E	FY29E
P/E Multiple	16	15
Lead Acid EPS (Rs. )	60.7	67.6
Lead Acid TP (Rs.) (A)	974	1,014
Li-Ion TP (Rs.) (B)	63	141
Total TP (Rs.) (A+B)	1,035	1,155



## **Segmental results & Margin Profile**

Segmental Results (Consol)	2QFY26	1QFY26	QoQ growth	2QFY25	YoY growth	1HFY26	1HFY25	YoY growth
Revenues								
Lead acid	32,970	32,798	1%	31,501	5%	65,768	62,874	5%
Others (New Energy)	1,700	1,213	40%	1,007	69%	2,913	2,264	29%
TotalRevenue	34,670	34,011	2%	32,507	7%	68,681	65,138	5%
EBIT								
Lead acid	3,939	2,530	56%	3,158	25%	6,469	6,220	4%
Others (New Energy)	-487	-352	38%	-143	241%	-839	-85	891%
Total EBIT	3,452	2,178	59%	3,015	14%	5,630	6,135	-8%
EBIT Margins								
Lead acid	11.9%	7.7%	423 bps	10.0%	192 bps	9.8%	9.9%	-6 bps
Others (New Energy)	-28.7%	-29.0%	37 bps	-14.2%	-1447 bps	-28.8%	-3.7%	-2507 bps
Total EBIT	10.0%	6.4%	355 bps	9.3%	68 bps	8.2%	9.4%	-122 bps







## **Financial Summary**

Standal	one Fi	inancia	l Sta	atements
---------	--------	---------	-------	----------

Standalone Financial Statements										
Rs mn	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E	FY29E
Profit & Loss										
Revenue	68,395	71,497	86,958	1,03,897	1,12,603	1,24,049	1,35,119	1,45,600	1,55,784	1,66,956
Gross profit	23,923	24,050	25,745	33,917	37,262	39,978	43,403	48,808	52,222	55,967
EBITDA	10,986	11,157	10,226	14,350	16,214	16,291	16,763	20,393	21,819	23,384
Depreciation	3,007	3,192	3,957	4,504	4,787	4,921	5,459	5,887	6,276	6,599
EBIT	7,978	7,965	6,269	9,846	11,427	11,370	11,304	14,505	15,543	16,785
Other Income	551	874	780	896	1,015	933	780	1,021	1,409	1,130
Interest expense	122	105	151	296	332	422	359	359	377	396
Exceptional items	0	0	0	-477	0	1,111	1,218	0	0	0
PBT	8,407	8,733	6,898	9,970	12,110	12,992	12,943	15,167	16,575	17,519
Reported PAT (after minority interest)	6,608	6,468	5,113	7,307	9,059	9,639	9,672	11,352	12,406	13,113
Adj PAT	6,608	6,468	5,113	7,316	9,059	9,639	8,665	11,352	12,406	13,113
EPS (Rs.)	38.7	37.9	29.9	42.8	49.5	52.7	47.3	62.0	67.8	71.7
Balance Sheet										
Net Worth	36,556	42,130	45,514	60,056	67,687	73,783	81,545	90,655	1,00,612	1,11,135
Total debt	343	234	165	1,111	533	1,445	945	745	645	545
Other liabilities and provisions	6,516	7,735	9,701	9,656	10,840	13,505	14,710	15,851	16,959	18,176
Total Networth and liabilities	43,857	50,506	55,694	71,860	79,945	89,465	97,932	1,07,983	1,18,948	1,30,588
Gross Fixed assets	29,337	38,784	43,116	59,580	62,988	67,152	73,152	78,152	83,152	88,652
Net fixed assets	18,292	24,548	24,923	36,882	35,503	34,747	35,288	34,400	33,124	32,025
Capital work-in-progress	8,270	3,993	8,297	2,343	3,217	8,441	8,441	8,441	8,441	8,441
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Investments	1,562	2,805	778	4,860	14,791	19,979	28,355	30,907	41,898	52,464
Cash and bank balances	845	1,758	536	998	1,045	1,653	363	6,991	6,335	6,417
Loans & advances and other assets	3,247	2,610	3,262	9,741	5,522	3,318	3,614	3,894	4,166	4,465
Net working capital	11,641	14,792	17,899	17,035	19,868	21,327	21,872	23,351	24,984	26,776
Total assets	43,857	50,506	55,694	71,860	79,945	89,465	97,932	1,07,983	1,18,948	1,30,588
Capital Employed	37,341	42,771	45,993	62,203	69,105	75,960	83,222	92,133	1,01,989	1,12,413
Invested Capital (CE - cash - CWIP)	28,226	37,021	37,161	58,862	64,844	65,866	74,418	76,701	87,213	97,555
Net debt	-1,924	-4,258	-718	-125	-3,161	-832	582	-6,245	-5,690	-5,872
Cash Flow										
Cash flows from Operations (Pre-tax)	14,133	10,016	8,323	12,125	16,431	17,035	18,766	20,436	22,055	23,244
Cash flows from Operations (post-tax)	11,769	8,020	6,330	9,562	13,142	13,752	15,495	16,622	17,886	18,838
Capex	7,014	4,967	7,609	4,659	4,423	7,518	6,000	5,000	5,000	5,500
Free cashflows	4,755	3,054	-1,280	4,904	8,719	6,234	9,495	11,622	12,886	13,338
Free cashflows (post interest costs)	4,633	2,948	-1,280	4,904	8,719	6,234	9,495	11,622	12,886	13,338
Cash flows from Investing	-8,497	-6,350	-4,819	-7,892	-10,720	-11,543	-14,375	-7,552	-15,991	-16,066
Cash flows from Financing	-3,638	-1,215	-2,135	-1,119	-2,425	-1,566	-2,410	-2,442	-2,550	-2,690
	845	1,758	536	1,236	3,694	2,278	363	6,991	6,335	6,417




## **Financial Summary**

#### **Standalone Financial Statements**

Standalone Financial Statements										
Growth ratios (%)	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E	FY29E
Revenue	0.7%	4.5%	21.6%	19.5%	8.4%	10.2%	8.9%	7.8%	7.0%	7.2%
EBITDA	15.4%	1.6%	-8.3%	40.3%	13.0%	0.5%	2.9%	21.7%	7.0%	7.2%
Adj PAT	36.7%	-2.1%	-21.0%	42.9%	24.0%	6.4%	0.3%	17.4%	9.3%	5.7%
Margin ratios (%)										
Gross	35.0%	33.6%	29.6%	32.6%	33.1%	32.2%	32.1%	33.5%	33.5%	33.5%
EBITDA	16.1%	15.6%	11.8%	13.8%	14.4%	13.1%	12.4%	14.0%	14.0%	14.0%
Adj PAT	9.7%	9.0%	5.9%	7.0%	8.0%	7.8%	6.4%	7.8%	8.0%	7.9%
Performance ratios										
Pre-tax OCF/EBITDA (%)	128.6%	89.8%	81.4%	84.5%	101.3%	104.6%	112.0%	100.2%	101.1%	99.4%
OCF/IC (%)	41.7%	21.7%	17.0%	16.2%	20.3%	20.9%	20.8%	21.7%	20.5%	19.3%
RoE (%)	18.9%	16.4%	11.7%	13.9%	14.2%	13.6%	11.2%	13.2%	13.0%	12.4%
RoCE (%)	18.6%	16.3%	11.8%	14.6%	14.2%	12.6%	11.3%	13.3%	13.1%	12.5%
RoCE (Pre-tax) (%)	23.7%	22.1%	15.9%	19.9%	19.0%	17.0%	15.2%	17.7%	17.5%	16.7%
Fixed asset turnover (x)	2.5	2.1	2.1	2.0	1.8	1.9	1.9	1.9	1.9	1.9
Total asset turnover (x)	1.6	1.5	1.6	1.6	1.5	1.5	1.4	1.4	1.4	1.3
Financial stability ratios										
Net Debt to Equity (x)	(0.1)	(0.1)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	(0.1)	(0.1)	(0.1)
Net Debt to EBITDA (x)	(0.2)	(0.4)	(0.1)	(0.0)	(0.2)	(0.1)	0.0	(0.3)	(0.3)	(0.3)
Interest cover (x)	96.5	76.2	41.9	32.3	39.6	32.6	43.2	46.3	47.4	47.6
Cash conversion days	62	76	75	60	64	63	59	59	59	59
Total Working capital days	45	49	48	60	47	33	29	29	29	29
Valuation metrics										
Fully Diluted Shares (mn)	170.8	170.8	170.8	170.8	183.0	183.0	183.0	183.0	183.0	183.0
Market cap (Rs.mn)		1,79,358								
P/E (x)	25.3	25.9	32.7	22.9	19.8	18.6	20.7	15.8	14.5	13.7
P/Sales (x)	2.6	2.5	2.1	1.7	1.6	1.4	1.3	1.1	1.1	1.0
EV (Rs.mn) (ex-CWIP)	1,69,164	1,77,834	1,78,988	1,79,233	1,76,197	1,78,526	1,79,940	1,73,113	1,73,669	1,73,486
EV/ EBITDA (x)	15.4	15.9	17.5	12.5	10.9	11.0	10.7	8.5	8.0	7.4
EV/ OCF(x)	14.4	22.2	28.3	18.7	13.4	13.0	11.6	10.4	9.7	9.2
FCF Yield (%)	2.7%	1.7%	-0.7%	2.7%	4.9%	3.5%	5.3%	6.5%	7.2%	7.4%
Price to BV (x)	4.9	4.3	3.9	3.0	2.6	2.4	2.2	2.0	1.8	1.6
Dividend yield (%)	50.1%	13.2%	33.4%	7.9%	15.1%	19.7%	19.7%	19.7%	19.7%	19.7%
Dividend pay-out (%)	2.0%	0.5%	1.0%	0.3%	0.8%	1.1%	1.1%	1.2%	1.4%	1.4%



## **Crystal Ball Gazing**



Source: Company data, Avendus Spark Research



### **Disclaimers and Disclosures**

This Report has been prepared on the basis of the facts, figures and information, which is already available in publicly accessible media or sources believed to be reliable or developed through an independent analysis by the Analysts of SIE. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. While we would endeavor to update the information herein on a reasonable basis, SIE and its affiliates are under no obligation to update the information. Also, there may be regulatory, compliance, or other reasons that prevent SIE and its affiliates from doing so. Neither SIE nor its affiliates or their respective directors, employees, agents, or representatives shall be responsible or liable in any manner, directly, for views or opinions expressed in this report or the contents or any errors or discrepancies herein or for any decisions or actions taken in reliance on the report or the inability to use or access our service in this report or for any loss or damages whether direct or indirect, incidental, special or consequential including without limitation loss of revenue or profits that may arise from or in connection with the use of or reliance on this report.

SIE and/or its affiliates and/or employees may have interests/positions, financial or otherwise, in the securities mentioned in this Report. To enhance transparency, SIE has incorporated disclosure of interest statement in this document. This should however not be treated as an endorsement of views expressed in this Report.

#### DISCLOSURE OF INTEREST & MATERIAL CONFLICT OF INTEREST STATEMENT:

SIE with its affiliates (reference shall individually or collectively refer to its respective relevant SIE's affiliates as the context may require):

- i. Are engaged in multiple financial service businesses inter-alia investment / merchant banking, lending, broking, distribution, wealth management, asset management, portfolio management, equity capital markets services including institutional equities & research;
- ii. Actual, potential, or apparent conflict of interest may arise as a result of various business activities carried out by SIE and its affiliates.
- iii. SIE and its affiliates and / or its respective personnel and / or its advisors may in future engage in activities that may result in conflict which may not have been captured herein.
- iv. SIE and its affiliates has policies and procedures in place for addressing such conflicts. SIE, its affiliates and its directors/partners/employees shall exercise a standard of good faith in its dealings.

SIE and/or its affiliates and/or employees and/or their relative(s) may have a financial interest in the subject company. SIE and/or its affiliates may have actual/beneficial ownership of one percent or more securities of the subject company or may from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein at the end of the month immediately preceding the date of publication of the Research Report. SIE and/or its associates and/or its employees have not been engaged in market making activity for the subject company.

- In the last twelve-month period ending on the last day of the month immediately preceding the date of publication of the Research Report, SIE and/or its affiliates and/or employees may have:
- i. managed/co-managed public offering of securities for the subject company;
- ii. received compensation for investment banking/merchant banking/brokerage services / other products/ services of the group from the subject company of this Research Report;
- iii. engaged in any other transaction involving such securities and earn fees or other compensation as an advisor or lender/borrower to subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions at the time of publication of Research Report or at the time of public appearance.
- iv. provided services to the subject company as a client.
- v. Research Analyst views on subject company may vary based on Fundamental research and Technical Research Team as all the activities are segregated from SIE's research activity and therefore it can have an independent view (including take contrary view / investment advise / investment exposure) with regards to subject company for which Research Team have expressed their views.

The affiliates of SIE has not received any compensation or other benefits from third party in connection with the research report

However, the above shall have no bearing on the specific recommendation made by the Analyst(s), as the recommendations or views as expressed in

Research Reports are not exchange traded products, and hence disputes relating to research activities of SIE do not have access to exchange investor redressal or Arbitration mechanism. We also hereby declare that our activities were neither suspended nor have we defaulted with any Stock Exchange authority with whom we are registered in the last five years. We have not been debarred from doing business by any Stock Exchange/SEBI or any other competent authorities, nor has our certificate of registration been cancelled by SEBI at any point in time.

Use of Artificial Intelligence tools: SIE does not use any Artificial Intelligence tools in providing research services.

#### ADDITIONAL DISCLAIMER FOR US INVESTORS:

SIE is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934 and under applicable state laws in the United States, as amended. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by SIE, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b) under the Securities Exchange Act of 1934 and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This Research Report must not be acted on or relied on by persons who are not major institutional investors.

SIE has entered into a chaperoning agreement with a U.S. registered broker-dealer, Avendus Capital Inc ("ACI"), affiliate a FINRA registered broker-dealer (CRD # 150160) in the State of Delaware with its principal office at 445 Park Avenue, 19th Floor, New York 10022, Any investment or investment or investment activity to which this Research Report relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. This research report is distributed in the United States by ACI, accepts responsibility its dissemination in the United States. Further, ACI has not authored this research report nor has independently verified any of the data presented within this report. The information provided is based on the research and analysis conducted by SIE. ACI does not recommend nor endorse this report. Furthermore, ACI does not have any direct business relationships with SIE nor does receive any direct compensation for the distribution of this report.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, ACI, and therefore, may not be subject to FINRA Rule 2241 restrictions on communications restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### ADDITIONAL DISCLAIMER FOR UK INVESTORS:

For the purposes of distribution within the United Kingdom, this communication is exempt from the financial promotion restriction in Section 21 of the Financial Services and Markets Act, 2000 relating to the communication or inducement to engage in investment activity on the grounds that it is made to those persons falling within the following Articles of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended: Article 49 (High Net Worth Companies). Any investment to which this communication relates is only available to investment professionals and high net worth companies.

#### CERTIFICATION BY EACH OF THE AUTHORS OF THIS REPORT:

The Analyst certifies that the views expressed in this Research Report are a representation of the Analyst's personal opinions on the stock or sector as covered and reported. The Analyst is principally responsible for the preparation of this Research Report and does not have any material conflict of interest at the time of publication of this Report. The Analyst(s) has not served as an officer, director, or employee of the subject company in the last 12 month period ending on the last day of the month immediately preceding the date of publication of the Research Report. The Analyst does not have actual/beneficial ownership of one per cent or more of the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report.

Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

### Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Spark Institutional Equities Private Limited is a financial services company incorporated in India, with its registered address at EA Chambers Tower II, No 49, 50, 5th floor, Whites Road, Royapettah, Chennai – 600 014



### **Spark Recommendation History**



Stock expected to provide positive returns of >15% over a 1-year horizon

Stock expected to provide returns of <5% – -10% over a 1-year horizon

Stock expected to fall >10% over a 1-year horizon

Stock expected to provide positive returns of >5% – <15% over a 1-year horizon

Rs. 2,000 ¬	,	ARENM IN Equ	ity – 3 Year Pri	ce and Rating H	History		
1,500 -				Manuel			
1,000 -		لسمسر	my of the same	, MA	human	<u></u>	Report Date
500 -			**			•	Target
0	1	1	1		ı	т	
	May-23	Nov-23	May-24	Nov-24	May-25	Oct-25	

25	02
25	#N
	#N

Report Date	CMP (Rs.)	TP (Rs.)	Reco.
19-Aug-25	958	1,030	ADD
02-Jun-25	1,031	1,085	ADD
11-Feb-25	1,032	1,150	ADD
07-Nov-24	1,330	1,400	ADD
07-Aug-24	1,465	1,200	REDUCE
31-May-24	1,180	1,200	ADD
05-Feb-24	895	920	ADD
02-Nov-23	618	720	ADD
#N/A	#N/A	#N/A	#N/A
#N/A	#N/A	#N/A	#N/A
#N/A	#N/A	#N/A	#N/A
#N/A	#N/A	#N/A	#N/A
#N/A	#N/A	#N/A	#N/A
#N/A	#N/A	#N/A	#N/A
#N/A	#N/A	#N/A	#N/A

#### No Change | ▼ Downgrade | ▲ Upgrade

**Absolute Rating Interpretation** 

**Symbol Interpretation** 

#### DISCLAIMER:

BUY

ADD

SELL

REDUCE

Spark Institutional Equities Private Limited ("SIE") holds a SEBI Research Analyst license (Registration No.INH200009722) and is primarily engaged in the business of institutional equities broking and research. SIE is registered with SEBI as a Stockbroker (member of BSE Limited and the National Stock Exchange of India Limited) and a Research

SIE's affiliates include (1) Avendus Capital Private Limited, holding Company of SIE, is a SEBI registered Merchant Banker (2) Avendus Wealth Management Private Limited is a SEBI registered Portfolio Manager, Stock Broker, Investment Advisor, Depository Participant (with NSDL), an investment manager to a Category III Alternative Investment Fund ("AIF"), AMFI registered Mutual Fund distributor, and registered with United States Securities and Exchange Commission (US SEC) as a Registered Investment Advisor Private Limited is an investment manager to a SEBI Registered Category II AIF. (4) Avezo Advisors Private Limited is an investment manager to SEBI Registered Category II AIF (5) Avendus Capital Public Markets Alternate Strategies LLP is an investment manager to SEBI registered Category III AIF (6) Avendus Investment Managers Private Limited is a SEBI registered Portfolio Manager and an investment manager to SEBI registered Category III AIF (7) Avendus Finance Private Limited which is registered with RBI as Non-Banking Finance Company (8) Avendus Capital Inc which is Broker dealer registered with State Securities Regulator of New York, New Jersey, Texas and California (9) Avendus Capital Pte Limited (Avendus Singapore), registered with Monetary Authority of Singapore ("MAS") and has Capital Markets Services (CMS) License to conduct corporate finance advisory and dealing in capital markets products (11) Zodius Growth LLP is Singapore fund entity managed by Avendus Singapore.

We offer our research services to clients as well as our prospects.

The information and opinion expressed in this Report does not constitute an offer or an invitation to make an offer to buy or sell any securities. None of the Analysts of SIE accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion, and other subjective judgments contained herein are made as of the date of this Research Report. This Research Report does not claim to contain all information that an investor may require for making an investment. The past performance of a product or portfolio does not in any manner indicate the surety of the performance in the future. This Report also does not constitute a personal recommendation or take into account the particular investment objectives, financial situations or needs of individual clients. SIE also has a separate team that puts together Technical Analysis / Alternative Research and each recipient of this report must note that the views of the Technical Analyst is always based on short term market variables and will be materially different from the views of the other Sector Analysts in SIE, whose reports are based on fundamental analysis of the Company.

Each recipient of this document should make such analysis as it deems necessary to arrive at an investment in the securities of the companies referred to in this document and should consult their own advisors to determine the merits and risks of such an investment. The price and value of the investments referred to in this Research Report and the income from them may go up or down and investors may realize losses on their investments. This Research Report is provided by SIE on a strictly confidential basis for the exclusive use of the recipient and should not be reproduced, redistributed, or passed on, directly or indirectly, to any other person or published, copied, in whole, or in part, for any purpose. SIE does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment.

This Research Report is not directed or intended for distribution to or use by any person or entity who is a citizen or resident of or located in any locality, state, country, or other jurisdiction, where such distribution, publication, availability, or use would be contrary to law, regulation or which would subject SIE and/or its affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this document may come are required to inform themselves of and observe such applicable restrictions. This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. Recipients shall be solely liable for any liability incurred by them in this regard and will indemnify SIE and/or its affiliates for any liability it may incur in this respect.

Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices, and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the provisions as may be applicable pursuant to it. Certain statements made herein may not be based on historical information or facts and may appear to be "Forward Looking Statements" including those relating to general business plans, future financial condition, and growth prospects. The actual results may differ materially from any "Forward- Looking statements" due to a number of factors, including socio, political, competitive environment, force majeure, etc. SIE makes no representation or warranty, express or implied, as to the accuracy, completeness, or fairness of the information and opinions contained in this document. SIE, its affiliates, and the employees of SIE and its affiliates may, from time to time, effect or have effected an own account transaction in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from, and any company referred to in this report.



### **Disclaimers and Disclosures**

This Report has been prepared on the basis of the facts, figures and information, which is already available in publicly accessible media or sources believed to be reliable or developed through an independent analysis by the Analysts of SIE. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. While we would endeavor to update the information herein on a reasonable basis, SIE and its affiliates are under no obligation to update the information. Also, there may be regulatory, compliance, or other reasons that prevent SIE and its affiliates from doing so.

Neither SIE nor its affiliates or their respective directors, employees, agents, or representatives shall be responsible or liable in any manner, directly or indirectly, for views or opinions expressed in this report or for any loss or damages whether direct or indirect, incidental, special or consequential including without limitation loss of revenue or profits that may arise from or in connection with the use of or reliance on this report.

SIE and/or its affiliates and/or employees may have interests/positions, financial or otherwise, in the securities mentioned in this Report. To enhance transparency. SIE has incorporated disclosure of interest statement in this document. This should however not be treated as an endorsement of views expressed in this Report.

#### DISCLOSURE OF INTEREST & MATERIAL CONFLICT OF INTEREST STATEMENT:

SIE with its affiliates (reference shall individually or collectively refer to its respective relevant SIE's affiliates as the context may require):

- i. Are engaged in multiple financial service businesses inter-alia investment / merchant banking, lending, broking, distribution, wealth management, asset management, portfolio management, equity capital markets services including institutional equities & research;
- ii. Actual, potential, or apparent conflict of interest may arise as a result of various business activities carried out by SIE and its affiliates.
- iii. SIE and its affiliates and / or its respective personnel and / or its advisors may in future engage in activities that may result in conflict which may not have been captured herein.
- iv. SIE and its affiliates has policies and procedures in place for addressing such conflicts. SIE, its affiliates and its directors/partners/employees shall exercise a standard of good faith in its dealings.

SIE and/or its affiliates and/or employees and/or their relative(s) may have a financial interest in the subject company. SIE and/or its affiliates may have actual/beneficial ownership of one percent or more securities of the subject company or may from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein at the end of the month immediately preceding the date of publication of the Research Report. SIE and/or its associates and/or its employees have not been engaged in market making activity for the subject company.

- In the last twelve-month period ending on the last day of the month immediately preceding the date of publication of the Research Report, SIE and/or its affiliates and/or employees may have:
- i. managed/co-managed public offering of securities for the subject company;
- ii. received compensation for investment banking/merchant banking/brokerage services / other products/ services of the group from the subject company of this Research Report;
- iii. engaged in any other transaction involving such securities and earn fees or other compensation as an advisor or lender/borrower to subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions at the time of publication of Research Report or at the time of public appearance.
- iv. provided services to the subject company as a client.
- v. Research Analyst views on subject company may vary based on Fundamental research and Technical Research Team as all the activities are segregated from SIE's affiliates maintains arm's length distance with Research Team as all the activities are segregated from SIE's research activity and therefore it can have an independent view (including take contrary view / investment advise / investment advise / investment exposure) with regards to subject company for which Research Team have expressed their views.

The affiliates of SIE has not received any compensation or other benefits from third party in connection with the research report

However, the above shall have no bearing on the specific recommendation made by the Analyst(s), as the recommendations or views as expressed in this report.

Research Reports are not exchange traded products, and hence disputes relating to research activities of SIE do not have access to exchange investor redressal or Arbitration mechanism. We also hereby declare that our activities were neither suspended nor have we defaulted with any Stock Exchange authority with whom we are registered in the last five years. We have not been debarred from doing business by any Stock Exchange/SEBI or any other competent authorities, nor has our certificate of registration been cancelled by SEBI at any point in time.

Use of Artificial Intelligence (AI) tools: AI tools are used solely for extracting and summarizing publicly available data within a predefined structure. All output derived, along with any supporting derivations included in the report, if any, are reviewed by the analysts to ensure accuracy and quality standards.

#### ADDITIONAL DISCLAIMER FOR US INVESTORS:

SIE is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934 and under applicable state laws in the United States, as amended. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by SIE, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b) under the Securities Exchange Act of 1934 and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This Research Report must not be acted on or relied on by persons who are not major institutional investors.

SIE has entered into a chaperoning agreement with a U.S. registered broker-dealer, Avendus Capital Inc ("ACI"), affiliate a FINRA registered broker-dealer (CRD # 150160) in the State of Delaware with its principal office at 445 Park Avenue, 19th Floor, New York 10022. Any investment or investment or investment activity to which this Research Report relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act ") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. This research report is distributed in the United States by ACI, accepts responsibility its dissemination in the United States. Further, ACI has not authored this research report nor has independently verified any of the data presented within this report. The information provided is based on the research and analysis conducted by SIE. ACI does not recommend nor endorse this report. Furthermore, ACI does not have any direct business relationships with SIE nor does receive any direct compensation for the distribution of this report.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, ACI, and therefore, may not be subject to FINRA Rule 2241 restrictions on communications restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### ADDITIONAL DISCLAIMER FOR UK INVESTORS:

For the purposes of distribution within the United Kingdom, this communication is exempt from the financial promotion restriction in Section 21 of the Financial Services and Markets Act, 2000 relating to the communication of an invitation or inducement to engage in investment activity on the grounds that it is made to those persons falling within the following Articles of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended: Article 49 (High Net Worth Companies). Any investment to which this communication relates is only available to investment professionals and high net worth companies.

#### CERTIFICATION BY EACH OF THE AUTHORS OF THIS REPORT:

The Analyst certifies that the views expressed in this Research Report are a representation of the Analyst's personal opinions on the stock or sector as covered and reported. The Analyst is principally responsible for the preparation of this Research Report and does not have any material conflict of interest at the time of publication of this Report. The Analyst(s) has not served as an officer, director, or employee of the subject company in the last 12 month period ending on the last day of the month immediately preceding the date of publication of the Research Report. The Analyst does not have actual/beneficial ownership of one per cent or more of the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report.

Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

### Investment in securities market are subject to market risks. Read all the related documents carefully before investing.